<DOC>
	<DOCNO>NCT00884221</DOCNO>
	<brief_summary>The main purpose clinical research trial compare ongoing pregnancy rate two gonadotrophin control ovarian stimulation ( MENOPUR recombinant follicle-stimulating hormone ( FSH ) ) , cycle gonadotrophin-releasing hormone ( GnRH ) antagonist use prevention premature luteinizing hormone ( LH ) surge single embryo transfer blastocyst stage .</brief_summary>
	<brief_title>MENOPUR Gonadotrophin-releasing Hormone ( GnRH ) Antagonist Cycles With Single Embryo Transfer</brief_title>
	<detailed_description>This randomize , open-label , assessor-blind , parallel group , multicentre trial compare efficacy highly purify menotrophin ( MENOPUR ; Ferring ) recombinant FSH ( PUREGON/FOLLISTIM ; MSD/Merck ) woman undergo controlled ovarian stimulation follow GnRH antagonist protocol . The use oral contraceptive program trial cycle prohibit . On day 2-3 menstrual cycle , participant randomize 1:1 fashion treatment either highly purified menotrophin ( MENOPUR ) recombinant FSH , stimulation initiate . The gonadotrophin start dose 150 international unit ( IU ) daily first 5 day . Hereafter , participant see stimulation day 6 subsequently least every 2 day transvaginal ultrasound make monitor response stimulation . From stimulation day 6 onwards , dose could adjust accord individual patient response purpose achieve 8-10 oocyte time oocyte retrieval . The dose adjustment could 75 IU per adjustment could do frequently every 4 day . The maximum allow gonadotrophin dose 375 IU daily participant could treat gonadotrophin maximum 20 day . Coasting prohibit . The GnRH antagonist ( ORGALUTRAN/GANIRELIX ACETATE INJECTION ; MSD/Merck ) initiate stimulation day 6 daily dose 0.25 mg continue throughout gonadotrophin treatment period . A single injection recombinant human chorionic gonadotrophin ( hCG ) 250 µg ( OVITRELLE/OVIDREL ; Merck Serono/EMD Serono ) administer induce final follicular maturation soon 3 follicle ≥ 17 mm observe ; i.e. , day reach hCG criterion next day . Oocyte retrieval take place 36h ( ± 2h ) hCG administration . Oocytes inseminate use partner sperm intracytoplasmic sperm injection ( ICSI ) 4h ( ± 1h ) retrieval . Oocyte , embryo blastocyst quality assess daily oocyte retrieval till 5 day . On day 5 oocyte retrieval , single blastocyst best quality available transfer remain blastocyst frozen . Vaginal progesterone capsule ( UTROGESTAN ; Seid ) 600 mg/day provide luteal phase support day oocyte retrieval till day beta human chorionic gonadotrophin ( βhCG ) test ( 13-15 day embryo transfer ) ; prolong luteal phase support beyond time point allow . Clinical pregnancy confirm transvaginal ultrasound 5-6 week embryo transfer ongoing pregnancy confirm transvaginal ultrasound 10-11 week embryo transfer . Post-trial follow-up include pregnancy outcome ( e.g . live birth ) neonatal health fresh trial cycle . Additional post-trial activity include follow-up frozen embryo replacement cycle initiate within 1 year participant 's randomization date .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<criteria>Inclusion criterion : Informed Consent Documents sign prior screen evaluation In good physical mental health Premenopausal females 2134 year age Body mass index ( BMI ) 1825 kg/m2 Eligible intracytoplasmic sperm injection ( ICSI ) Unexplained infertility partner mild male factor infertility Infertility least 12 month randomization Regular menstrual cycle 2435 day , presumed ovulatory Hysterosalpingography , hysteroscopy , transvaginal ultrasound document uterus consistent expect normal function Transvaginal ultrasound document expect normal function ovary Early follicular phase serum level FSH 1 12 IU/L Early follicular phase total antral follicle ( diameter 210 mm ) count ≥ 10 ovary combine Willing accept transfer one blastocyst fresh cycle Willing undergo frozen embryo replacement cycle transfer one blastocyst per cycle within first year randomisation Exclusion criterion : Known polycystic ovarian syndrome know endometriosis stage IIV Diagnosed `` poor responder '' previous control ovarian stimulation ( COS ) cycle Severe ovarian hyperstimulation syndrome ( OHSS ) previous COS cycle History recurrent miscarriage Current past ( 12 month prior randomization ) abuse alcohol drug , and/or current ( last month ) intake 14 unit alcohol per week Current past smoking habit 10 cigarette per day Hypersensitivity active ingredient excipients medicinal product use trial Hypersensitivity gonadotrophinreleasing hormone ( GnRH ) GnRH analogue Previous participation trial Use non register investigational drug 3 month randomization</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>